PAHO provides new opportunity for Latin America and the Caribbean to access HIV drugs

WASHINGTON, United States (CMC) — The Pan American Health Organization (PAHO) says it is providing new opportunities for Latin America and the Caribbean (LAC) to access lenacapavir as part of preventive medicine to curb the spread of HIV throughout the region.

PAHO said that the medication will be made available through its Regional Revolving Funds, under an agreement with Gilead Sciences and that the initiative will make the long-acting HIV prevention medicine available to 14 countries.

“The agreement between Gilead and PAHO reflects our shared commitment to help countries move as quickly as possible from scientific innovation to real-world access to HIV prevention and public health impact,” said Johanna Mercier, chief commercial & corporate affairs officer, Gilead Sciences.